Glycoengineered Type II Anti-CD20 Monoclonal Antibody

Mechanism

Related News

Obinutuzumab Achieves 37% Complete Remission vs 6% for Tacrolimus in Phase 3 PMN Trial

Jul 16, 2026

Phase 3 MAJESTY trial results show obinutuzumab led to 37% complete remission at 2 years vs 6% with tacrolimus in primary membranous nephropathy, with comparable safety. Genentech announced the positive data in February 2026, positioning obinutuzumab as a potential first approved therapy for PMN.

Obinutuzumab Shows Efficacy in Systemic Lupus and Primary Membranous Nephropathy Trials

Mar 06, 2026

Obinutuzumab demonstrated superior efficacy in two separate phase 3 trials for systemic lupus erythematosus and primary membranous nephropathy, with statistically significant improvements in remission rates and disease response measures.